Tearsheet

China SXT Pharmaceuticals (SXTC)


Market Price (10/31/2025): $1.34 | Market Cap: $-
Sector: Health Care | Industry: Pharmaceuticals

China SXT Pharmaceuticals (SXTC)


Market Price (10/31/2025): $1.34
Market Cap: $-
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0  Weak multi-year price returns
2Y Excs Rtn is -158%, 3Y Excs Rtn is -176%
High stock price volatility
Vol 12M is 571%
0 Weak multi-year price returns
2Y Excs Rtn is -158%, 3Y Excs Rtn is -176%
1 High stock price volatility
Vol 12M is 571%

Market Valuation & Key Metrics

SXTC Stock


Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
SXTC Return-60%-51%-96%-71%-87%-67%-100%
Peers Return-10%-6%-26%-27%-27%2488%759%
S&P 500 Return16%27%-19%24%23%16%110%

Monthly Win Rates [3]
SXTC Win Rate50%17%25%33%42%33% 
Peers Win Rate22%30%22%23%32%44% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
SXTC Max Drawdown-72%-57%-96%-87%-92%-92% 
Peers Max Drawdown-17%-13%-31%-34%-35%-27% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: BGM, NSRX, RGC, RHHBY, SXTC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique KeyEventSXTCS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-99.9%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven147467.4%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-83.9%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven522.0%51.3%
2020 Covid PandemicTime to BreakevenTime to BreakevenNot Fully Recovered days148 days

Compare to BGM, NSRX, RGC, RHHBY, SXTC


In The Past

China SXT Pharmaceuticals's stock fell -99.9% during the 2022 Inflation Shock from a high on 2/16/2021. A -99.9% loss requires a 147467.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About China SXT Pharmaceuticals (SXTC)

Trade Ideas

Select past ideas related to SXTC. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
4.2%4.2%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
16.3%16.3%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
3.8%3.8%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
14.0%14.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
13.5%13.5%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
4.2%4.2%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
16.3%16.3%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
3.8%3.8%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
14.0%14.0%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
13.5%13.5%-8.0%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for China SXT Pharmaceuticals

Financials

SXTCBGMNSRXRGCRHHBYMedian
NameChina SX.BGM Nasus Ph.Regencel.Roche  
Mkt Price1.369.127.7816.3540.569.12
Mkt Cap------
Rev LTM------
Op Inc LTM------
FCF LTM------
FCF 3Y Avg------
CFO LTM------
CFO 3Y Avg------

Growth & Margins

SXTCBGMNSRXRGCRHHBYMedian
NameChina SX.BGM Nasus Ph.Regencel.Roche  
Rev Chg LTM------
Rev Chg 3Y Avg------
Rev Chg Q------
QoQ Delta Rev Chg LTM------
Op Mgn LTM------
Op Mgn 3Y Avg------
QoQ Delta Op Mgn LTM------
CFO/Rev LTM------
CFO/Rev 3Y Avg------
FCF/Rev LTM------
FCF/Rev 3Y Avg------

Valuation

SXTCBGMNSRXRGCRHHBYMedian
NameChina SX.BGM Nasus Ph.Regencel.Roche  
Mkt Cap------
P/S------
P/EBIT------
P/E------
P/CFO------
Total Yield------
Dividend Yield------
FCF Yield 3Y Avg------
D/E------
Net D/E------

Returns

SXTCBGMNSRXRGCRHHBYMedian
NameChina SX.BGM Nasus Ph.Regencel.Roche  
1M Rtn-13.4%-10.9%17.0%5.8%-3.0%-3.0%
3M Rtn-12.8%7.8%-23.9%4.2%6.0%
6M Rtn-38.7%-19.3%-706.9%2.5%-8.4%
12M Rtn-70.6%23.1%-8,893.4%6.2%14.6%
3Y Rtn-98.9%--2,156.1%14.1%14.1%
1M Excs Rtn-16.7%-12.2%28.0%1.6%-11.2%-11.2%
3M Excs Rtn-29.4%-3.3%-16.7%-4.9%-4.1%
6M Excs Rtn-60.5%-41.0%-685.2%-19.3%-30.1%
12M Excs Rtn-88.3%-0.8%-10,069.8%-13.2%-7.0%
3Y Excs Rtn-175.7%--2,079.3%-63.7%-63.7%

Financials

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity123,633
Short Interest: % Change Since 9302025-14.9%
Average Daily Volume21,425
Days-to-Cover Short Interest5.77

SEC Filings

Expand for More

Report DateFiling DateFiling
3312025731202520-F 3/31/2025
930202432820256-K 9/30/2024
3312024813202420-F 3/31/2024
930202340520246-K 9/30/2023
3312023731202320-F 3/31/2023
930202222420236-K 9/30/2022
3312022718202220-F 3/31/2022
930202111420226-K 9/30/2021
3312021813202120-F 3/31/2021
930202012820216-K 9/30/2020
3312020731202020-F 3/31/2020
930201942220206-K 9/30/2019
3312019815201920-F 3/31/2019
930201832820196-K 9/30/2018
331201810032018424B4 3/31/2018

Insider Activity

Expand for More